Company

Abarceo Pharma AB

Biotechnology Research Se 9 employees

Employees: 9
Contacts: 3
Emails: 3

www.abarceo.com LinkedIn

Abarceo Pharma AB Overview

Headquarters: Se
Website: www.abarceo.com
Industry: Biotechnology Research
Employees: 9
Founded: 2017
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

beta cell dysfunction VDAC-1 drug development drug discovery Alzheimer's Mitochondria Type 1 Diabetes

About Abarceo Pharma AB

Abarceo is a preclinical stage company. The company has expertise in the molecular and genetic causes of beta cell dysfunction in type 2 diabetes and has identified a novel diabetes target responsible for the dysfunction, VDAC-1. By blocking VDAC-1 with a small molecule blocker beta cells are returned to a functional state in a durable and disease modifying manner allowing patients to produce sufficient insulin, naturally. The company is fundraising to support preclinical development.

Abarceo Pharma AB Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage

Abarceo Pharma AB Org Chart

Sample employees and titles

Name	Title	Location	Contact
Ruchi Jain	Principal Scientist at Abarceo Pharma	Sweden	Email
Cornelia Nilsson	Molecular Biology Student at Lund	Lund, Skåne County, Sweden	View
Kishan Bellamkonda, Phd	Senior Scientist @ Abarceo Pharma	Lund, Skåne County, Sweden	Email
Mathias Wollheim		Switzerland	Email